These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31609811)

  • 1. Rheumatoid Arthritis Patient's Journey: Delay in Diagnosis and Treatment.
    Rosa JE; García MV; Luissi A; Pierini F; Sabelli M; Mollerach F; Soriano ER
    J Clin Rheumatol; 2020 Oct; 26(7S Suppl 2):S148-S152. PubMed ID: 31609811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of delay in assessment of patients with early arthritis.
    van der Linden MP; le Cessie S; Raza K; van der Woude D; Knevel R; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2010 Dec; 62(12):3537-46. PubMed ID: 20722031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis.
    Rodríguez-Polanco E; Al Snih S; Kuo YF; Millán A; Rodríguez MA
    Rheumatol Int; 2011 May; 31(5):657-65. PubMed ID: 20066425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to treatment for new patients with rheumatoid arthritis in a major metropolitan city.
    Jamal S; Alibhai SM; Badley EM; Bombardier C
    J Rheumatol; 2011 Jul; 38(7):1282-8. PubMed ID: 21572157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
    Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
    Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial.
    Tavares R; Beattie KA; Bensen WG; Bobba RS; Cividino AA; Finlay K; Goeree R; Hart LE; Jurriaans E; Larche MJ; Parasu N; Tarride JE; Webber CE; Adachi JD
    Trials; 2014 Jul; 15():268. PubMed ID: 24997587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to consultation and disease-modifying antirheumatic drug treatment of patients with rheumatoid arthritis--northern Alberta perspective.
    Nanji JA; Choi M; Ferrari R; Lyddell C; Russell AS
    J Rheumatol; 2012 Apr; 39(4):707-11. PubMed ID: 22337235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
    Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
    Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice.
    Irvine S; Munro R; Porter D
    Ann Rheum Dis; 1999 Aug; 58(8):510-3. PubMed ID: 10419871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and therapeutic delay of rheumatoid arthritis and its relationship with health care devices in Catalonia. The AUDIT study.
    Corominas H; Narváez J; Díaz-Torné C; Salvador G; Gomez-Caballero ME; de la Fuente D; Campoy E; Roig-Vilaseca D; Clavaguera T; Morlà R; Torrente-Segarra V; Arasa X; Gomez-Puerta JA; Möller I; Alegre C; Graell E; Ponce A; Lisbona MP; Pérez-Garcia C; Fíguls R; Sirvent E; Poca V; Sanmartí R
    Reumatol Clin; 2016; 12(3):146-50. PubMed ID: 26362843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis.
    Hernández-García C; Vargas E; Abásolo L; Lajas C; Bellajdell B; Morado IC; Macarrón P; Pato E; Fernández-Gutiérrez B; Bañares A; Jover JA
    J Rheumatol; 2000 Oct; 27(10):2323-8. PubMed ID: 11036824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.
    Weng HH; Ranganath VK; Khanna D; Oh M; Furst DE; Park GS; Elashoff DA; Sharp JT; Gold RH; Peter JB; Paulus HE;
    J Rheumatol; 2010 Mar; 37(3):550-7. PubMed ID: 20110517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years.
    Aletaha D; Eberl G; Nell VP; Machold KP; Smolen JS
    Ann Rheum Dis; 2002 Jul; 61(7):630-4. PubMed ID: 12079906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.
    Benbouazza K; Benchekroun B; Rkain H; Amine B; Bzami F; Benbrahim L; Atouf O; Essakalli M; Abouqal R; Dougados M; Hajjaj-Hassouni N
    BMC Musculoskelet Disord; 2011 Nov; 12():266. PubMed ID: 22111841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence.
    Waimann CA; Marengo MF; de Achaval S; Cox VL; Garcia-Gonzalez A; Reveille JD; Richardson MN; Suarez-Almazor ME
    Arthritis Rheum; 2013 Jun; 65(6):1421-9. PubMed ID: 23728826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.
    Ornbjerg LM; Ostergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Ringsdal VS; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Dencker D; Hansen A; Andersen AR; Hetland ML
    Ann Rheum Dis; 2013 Jan; 72(1):57-63. PubMed ID: 22532636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.